Pertwee's 2008 review demolished the assumption that plant cannabinoids are pharmacologically interchangeable — showing that THC is a partial agonist, CBD is an antagonist, and THCV switches between blocking and activating receptors depending on dose.
Anyone wanting to understand why THC gets you high but CBD doesn't, why different cannabis products feel different, or the receptor-level science behind cannabinoid pharmacology.
3 profilesThree cannabinoids from the same plant with completely different receptor pharmacology: THC activates, CBD blocks, THCV does both depending on dose. Cannabis is not one drug — it's a cocktail of molecules with different and sometimes opposite effects.
The Backstory
For decades, the working assumption was simple: cannabinoids are cannabinoids. They come from the same plant, they hit the same receptors, they vary in potency. THC is the strong one. CBD is the mild one. The rest are background noise.
In 2008, Roger Pertwee — the same pharmacologist who had chronicled the field's 66-year history two years earlier — published a review that demolished that assumption. He showed that three major plant cannabinoids don't just differ in potency. They have completely different, sometimes opposite, pharmacological profiles at the very same receptors.
One activates. One blocks. One does both, depending on the dose.
Same plant. Three different drugs.
Three Molecules, Three Personalities
Δ9-THC
- CB1 partial agonist — activates, but not fully
- CB2 partial agonist — similar profile
- Produces the 'high' — psychoactive
- Stimulates appetite (munchies)
- Ceiling effect on activation (safety margin)
- Efficacy depends on receptor density and endocannabinoid tone
- Tolerance develops as receptors downregulate
The activator — but only partway
CBD
- CB1 antagonist / negative allosteric modulator
- CB2 antagonist at nanomolar concentrations
- Non-psychoactive — does NOT produce a high
- Blocks THC's ability to fully activate CB1
- Also acts on TRPV1, 5-HT1A, GPR55, PPARγ
- Anti-inflammatory via CB2 and non-CB targets
- Unexpectedly high potency as a blocker
The blocker — non-psychoactive, multi-target
Δ9-THCV
- CB1 antagonist at LOW doses
- CB1 agonist at HIGH doses
- CB2 partial agonist (consistent)
- Suppresses appetite at typical doses
- Improves glucose metabolism
- Non-psychoactive at low doses
- Dose-dependent pharmacological reversal
The shapeshifter — blocks or activates depending on dose
Pertwee (2008), Br J Pharmacol 153:199-215
This three-way comparison is the core insight of the paper — and it has implications for everything from product labeling to drug safety to why different cannabis preparations feel so different.
THC: The Partial Agonist
THC is the molecule everyone knows — the psychoactive component of cannabis, isolated by Mechoulam in 1964. But Pertwee's characterization added a critical nuance: THC is a partial agonist at CB1, not a full one.
What does that mean? A full agonist activates a receptor to its maximum capacity. A partial agonist activates it only partway — there's a ceiling on how much activation is possible, no matter how much of the drug you take. THC can never fully activate CB1. It gets you high, but there's a built-in limit.
This matters for two reasons:
- Plant THC (partial agonist) moderate
Activates CB1 partially. Ceiling effect limits maximum receptor activation. Cannot produce fatal respiratory depression. No confirmed overdose deaths from cannabis alone.
All cannabis users
- Synthetic cannabinoids / K2 / Spice (full agonists) very-high
Activate CB1 fully with no ceiling. Can cause seizures, psychosis, kidney injury, rhabdomyolysis, and death. Hundreds of documented fatalities. 2-100× more potent than THC.
Users of synthetic cannabinoid products
Pertwee (2008); Trecki et al. (2014)
The partial agonist profile also explains tolerance. As chronic THC exposure causes CB1 receptors to downregulate and desensitize, a partial agonist loses efficacy faster than a full agonist would — because it was already operating below maximum. This is why regular cannabis users need increasingly more THC to achieve the same effect, and why tolerance breaks work: the receptors recover, and partial agonism becomes effective again.
CBD: The Unexpected Blocker
Here's what most people get wrong about CBD:
Myth vs. Reality
CBD activates cannabinoid receptors more gently than THC — it's a milder version of the same thing.
CBD does not activate CB1 or CB2 receptors. It blocks them. Pertwee showed that CBD acts as an antagonist at both receptors with unexpectedly high potency. Later research refined this to 'negative allosteric modulator' — CBD binds a different site on the receptor and reduces THC's ability to activate it.
The Evidence
In cell lines and tissue preparations expressing CB1 or CB2 receptors, CBD displaced cannabinoid agonists and reduced their functional effects. Laprairie et al. (2015) demonstrated that CBD binds an allosteric site on CB1, reducing the potency and efficacy of both THC and 2-AG on downstream signaling (PLCβ3, ERK1/2). CBD also prevents CB1 receptor internalization by reducing β-arrestin2 recruitment.
Pertwee (2008), Br J Pharmacol; Laprairie et al. (2015), PMC4621983
This is why CBD doesn't get you high. It's not a weaker version of THC — it's pharmacologically opposite at cannabinoid receptors. And it's why adding CBD to THC changes the experience: CBD literally reduces THC's ability to activate CB1.
But CBD isn't pharmacologically empty just because it doesn't activate cannabinoid receptors. It's one of the most polyvalent molecules in pharmacology, hitting multiple non-cannabinoid targets:
Biological Mechanism
How CBD Works — Beyond Cannabinoid Receptors
CB1 negative allosteric modulation
Binds an allosteric site on CB1, reducing THC and 2-AG efficacy. This is why CBD modulates the THC high — it literally makes the receptor less responsive to activation.
TRPV1 activation
CBD activates vanilloid receptors (TRPV1) — the same receptors that detect heat and capsaicin. Desensitization of these receptors may contribute to pain-relieving and anti-inflammatory effects.
5-HT1A activation
CBD acts on serotonin 1A receptors, which are involved in anxiety and mood regulation. This may explain CBD's anxiolytic effects independently of the cannabinoid system.
GPR55 antagonism
CBD blocks GPR55, sometimes called a putative 'CB3' receptor. GPR55 activation promotes cancer cell proliferation in some models — blocking it may contribute to anti-cancer effects.
PPARγ activation
CBD activates nuclear receptors involved in anti-inflammatory gene regulation. This pathway operates independently of all cell-surface receptors.
Pertwee (2008); Laprairie et al. (2015); Ibeas Bih et al. (2015)
This multi-target profile — not cannabinoid receptor activation — is how CBD produces its therapeutic effects. It's also why CBD pharmacology is so hard to study: the effects come from at least five different receptor systems acting simultaneously.
For the practical question of how CBD and THC differ, this paper provides the definitive receptor-level explanation.
THCV: The Shapeshifter
The most pharmacologically surprising cannabinoid in the review is THCV — delta-9-tetrahydrocannabivarin. Structurally similar to THC (a propyl side chain instead of pentyl), THCV does something no other well-characterized cannabinoid does: it switches between antagonist and agonist depending on dose.
Dose-Response
THCV's Dose-Dependent Pharmacological Reversal at CB1
Pertwee (2008), Br J Pharmacol (conceptual representation based on pharmacological profile)
At low doses, THCV blocks CB1 — acting as an antagonist that suppresses appetite and is non-psychoactive. At high doses, it flips and activates CB1 — potentially producing mild psychoactive effects and appetite stimulation. At CB2, it's consistently a partial agonist regardless of dose.
This unique pharmacology has made THCV the most therapeutically interesting of the minor cannabinoids:
- Appetite suppression via CB1 antagonism — without the psychiatric side effects that killed rimonabant (because THCV is a neutral antagonist, not an inverse agonist)
- Improved glucose metabolism — a 2016 clinical trial showed THCV significantly decreased fasting plasma glucose and improved β-cell function in Type 2 diabetes patients
- Non-psychoactive at therapeutic doses — the antagonist range
The popular nickname "diet weed" undersells the pharmacology. THCV isn't just THC that doesn't make you hungry. It's a fundamentally different molecule at the receptor level.
Why One Plant Makes Three Different Drugs
Understanding these three pharmacological profiles explains almost every practical question about cannabis:
Why does CBD change the THC high? Because CBD blocks the receptor THC activates. Adding CBD to THC literally reduces THC's ability to bind and activate CB1. This is why high-CBD strains feel different from high-THC strains — it's receptor-level competition.
Why does tolerance develop? THC is a partial agonist — already operating below maximum receptor activation. When chronic use causes CB1 downregulation, a partial agonist loses its effect faster than a full agonist would. The gap between what THC can activate and what the remaining receptors allow narrows until the drug barely works.
Why are synthetic cannabinoids (K2/Spice) so dangerous? They're full agonists — no ceiling on receptor activation. Plant THC's partial agonism is a built-in safety mechanism. Remove that ceiling with a synthetic full agonist, and you get seizures, psychosis, and death.
Why do different THC:CBD ratios feel so different? Because the ratio determines the balance between activation (THC) and blockade (CBD) at the same receptor. A 1:1 product produces a different pharmacological profile than a 20:1 product — not just in degree, but in kind.
Why are THCV products marketed for weight management? Because at typical oral doses, THCV acts as a CB1 antagonist — suppressing the same appetite-stimulating pathway that THC activates. Same receptor, opposite effect, depending on which molecule gets there.
Related Research
From System to Molecules — The Pharmacology Chain
This paper translates the endocannabinoid system discoveries into practical cannabinoid pharmacology. These are the foundational studies it builds on.
Isolation, Structure, and Partial Synthesis of an Active Constituent of Hashish
Gaoni & Mechoulam (1964)
THC — the partial agonist whose structure made all subsequent pharmacology possible
Structure of a cannabinoid receptor and functional expression of the cloned cDNA
Matsuda et al. (1990)
CB1 — the receptor at the center of all three pharmacological profiles
Cannabinoid pharmacology: the first 66 years
Pertwee (2006)
The historical foundation — same author, two years earlier, telling the story that led to these insights
Molecular characterization of a peripheral receptor for cannabinoids
Munro et al. (1993)
CB2 — the immune receptor where all three cannabinoids also have distinct profiles
If CBD doesn't activate cannabinoid receptors, how does it work?
CBD blocks cannabinoid receptors (it's a negative allosteric modulator — it binds a different spot on CB1 and reduces THC's ability to activate it). But CBD also acts on at least four other receptor systems: TRPV1 (pain/heat receptors), 5-HT1A (serotonin receptors involved in anxiety), GPR55 (a putative cannabinoid receptor involved in cell proliferation), and PPARγ (nuclear receptors involved in inflammation). Its therapeutic effects come from this multi-target profile, not from cannabinoid receptor activation.
Why is plant THC safer than synthetic cannabinoids like K2/Spice?
THC is a partial agonist — it activates CB1 receptors but only partway, creating a natural ceiling on how much activation is possible. Synthetic cannabinoids are typically full agonists with no ceiling. This is why cannabis overdose is essentially non-fatal (the partial agonist ceiling limits toxicity) while synthetic cannabinoid overdoses can cause seizures, psychosis, organ damage, and death. The distinction between partial and full agonism is the pharmacological reason plant cannabis has an enormous safety margin compared to synthetic alternatives.
What the researchers found
Delta-9-THC functions as a CB1 and CB2 receptor partial agonist, with its efficacy depending on receptor expression levels and ongoing endocannabinoid tone. Cannabidiol (CBD) displays unexpectedly high potency as an antagonist of CB1 and CB2 receptor agonists — not activating the receptors but blocking them. Delta-9-THCV behaves as a potent CB2 receptor partial agonist in vitro while antagonizing cannabinoid receptor agonists in CB1-expressing tissues at low doses, but acting as a CB1 agonist at higher doses. All three compounds also interact with non-cannabinoid targets including TRPV1, 5-HT1A, and GPR55 receptors. The review additionally covers THC tolerance development, dose-response relationships, and therapeutic implications of each distinct pharmacological profile.
Why it matters
This review established that plant cannabinoids are not pharmacologically interchangeable — the same plant produces molecules with completely different, sometimes opposite, receptor pharmacology. This insight underpins the entire regulatory distinction between THC and CBD, explains why different cannabis preparations produce different effects, why CBD modulates the THC high, why synthetic full agonists (K2/Spice) are more dangerous than plant-derived THC, and why THCV is being developed for metabolic conditions. Without this pharmacological framework, cannabis medicine is guesswork.
The numbers in context
THC: partial agonist at CB1 and CB2. CBD: potent antagonist at CB1 and CB2. THCV: CB2 partial agonist, CB1 antagonist (low dose) or agonist (high dose). All three also interact with non-cannabinoid targets.
How the study worked
Comprehensive pharmacological review synthesizing published receptor binding data, functional assay results (including the mouse vas deferens bioassay), in vivo behavioral studies, and clinical observations for three major phytocannabinoids. The author integrated evidence from transfected cell lines, native tissue preparations, knockout mouse studies, and clinical pharmacology to characterize each compound's receptor interaction profile.
What this study cannot tell us
As a review, this paper synthesizes existing pharmacological data rather than generating new experiments. Much of the characterization was performed in cell lines and isolated tissue preparations — the in vivo pharmacology is more complex due to polyvalent receptor interactions, metabolite effects, and pharmacokinetic variables. The CBD characterization as an antagonist was later refined to "negative allosteric modulator" (Laprairie 2015). THCV dose-response data was primarily from animal models with limited human clinical confirmation at the time of publication.
How to read the evidence
Rated strong because this review synthesizes extensive receptor binding data, functional assay results, and behavioral pharmacology from dozens of studies. The characterizations have been independently confirmed by multiple groups and refined (CBD as NAM, THCV dose-response) without contradiction.
When this study was published
Published in 2008, this 18-year-old review remains the definitive single-document characterization of phytocannabinoid receptor pharmacology. The core profiles (THC partial agonist, CBD antagonist/NAM, THCV dose-dependent switch) have been confirmed and refined but not contradicted. CBD's mechanism was updated to negative allosteric modulation in 2015.
The bigger picture
This paper bridged the gap between endocannabinoid system discovery and practical cannabis pharmacology. Knowing that CB1 exists is one thing; knowing that THC partially activates it, CBD blocks it, and THCV does both depending on dose is what makes cannabinoid pharmacology useful. The CBD characterization directly enabled the regulatory logic behind the 2018 Farm Bill (CBD is not THC because it doesn't activate cannabinoid receptors). The THCV characterization spawned a therapeutic research program for obesity and diabetes. The THC partial agonism characterization explains why plant-derived THC has a ceiling effect while synthetic full agonists can be lethal.
Questions still open
- If CBD blocks cannabinoid receptors, how should its dose interact with THC in medical cannabis products?
- Can THCV's CB1 antagonist profile be therapeutically exploited for obesity without the psychiatric side effects that killed rimonabant?
- How do the 100+ other plant cannabinoids interact with CB1 and CB2 — are there more surprises?
Common questions
If CBD doesn't activate cannabinoid receptors, how does it work?
Why is plant THC safer than synthetic cannabinoids like K2/Spice?
Read the original research
The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: delta9-tetrahydrocannabinol, cannabidiol and delta9-tetrahydrocannabivarin.
British journal of pharmacology, 153(2), 199-215
Citation
Pertwee, R G. (2008). The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: delta9-tetrahydrocannabinol, cannabidiol and delta9-tetrahydrocannabivarin.. British journal of pharmacology, 153(2), 199-215. https://doi.org/10.1038/sj.bjp.0707442
Explore the wider topic
- How THC Affects Your Amygdala: The Brain's Threat Detector and Cannabis
- The Anandamide Connection: Your Body's Natural Bliss Molecule
- How Long for Cannabinoid Receptors to Return to Normal
- Cannabis and the Developing Brain: What Every Teenager (and Parent) Should Know
- Why Can't I Enjoy Anything Without Weed? The Science Behind It
- Dopamine Recovery After Quitting Weed: What the Science Says
- The Endocannabinoid System Explained Simply: What It Does and Why It Matters
- Your Endocannabinoid System Explained: Why Withdrawal Happens
- Your Nervous System After Quitting Weed: Fight or Flight
- Using Weed Under 18: What It Does to Your Developing Brain
- What THC Does to Your Brain: Why Withdrawal Happens
- THC and Your Prefrontal Cortex: What Cannabis Does to Your Decision-Making Brain
- Weed, Cortisol, and Stress: What Cannabis Does to Your Stress Hormones
- Weed and Memory: What the Science Says About THC and Your Hippocampus
- Weed and Motivation: Is Amotivational Syndrome Real?
- Weed and Your Nervous System: What THC Actually Does to Your Brain and Body
- How Weed Rewires Your Reward System (And How to Reset It)